Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma

OncoImmunology

Volumn 4, Issue 6, 2015, Pages

  Jasinski Bergner, Simon ^a   Stoehr, Christine ^b   Bukur, Juergen ^a   Massa, Chiara ^a   Braun, Juliane ^a   Hüttelmaier, Stefan ^a   Spath, Verena ^b   Wartenberg, Roland ^b   Legal, Wolfgang ^b   Taubert, Helge ^b   Wach, Sven ^b   Wullich, Bernd ^b   Hartmann, Arndt ^b   Seliger, Barbara ^a  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Immune escape; microRNA; Non classical HLA class I molecules; Renal cell carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

HLA G ANTIGEN; MICRORNA;

ADULT; AGED; ARTICLE; CELL ACTIVATION; CELL INFILTRATION; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; POLYMERASE CHAIN REACTION; TISSUE MICROARRAY; UNTRANSLATED REGION; WESTERN BLOTTING;

EID: 84944472773     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2015.1008805     Document Type: Article

References (58)

1. Hviid TV. HLA-G in human reproduction: aspects of genetics, function and pregnancy complications. Hum Reprod Update 2006; 12:209-32; PMID:16280356; http://dx.doi.org/10.1093/humupd/dmi048
2. Menier C, Rabreau M, Challier JC, Le Discorde M, Carosella ED, Rouas-Freiss N. Erythroblasts secrete the nonclassical HLA-G molecule from primitive to definitive hematopoiesis. Blood 2004; 104:3153-60; PMID:15284117; http://dx.doi.org/10.1182/blood-2004-03-0809
3. Colonna M, Navarro F, Bellon T, Llano M, Garcia P, Samaridis J, Angman L, Cella M, López-Botet M. A common inhibitory receptor for major histocompatibility complex class I molecules on human lymphoid and myelomonocytic cells. J Exp Med 1997; 186:1809-18; PMID:9382880; http://dx.doi. org/10.1084/jem.186.11.1809
4. Colonna M, Samaridis J, Cella M, Angman L, Allen RL, O'Callaghan CA, Dunbar R, Ogg GS, Cerundolo V, Rolink A. Human myelomonocytic cells express an inhibitory receptor for classical and nonclassical MHC class I molecules. J Immunol 1998; 160:3096-100; PMID:9531263
5. Rajagopalan S, Long EO. A human histocompatibility leukocyte antigen (HLA)-G-specific receptor expressed on all natural killer cells. J Exp Med 1999; 189:1093-100; PMID:10190900; http://dx.doi.org/10.1084/ jem.189.7.1093
6. Shiroishi M, Tsumoto K, Amano K, Shirakihara Y, Colonna M, Braud VM, Allan DS, Makadzange A, Rowland-Jones S, Willcox B et al. Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G. Proc Natl Acad Sci USA 2003; 100:8856-61; PMID:12853576; http://dx.doi.org/ 10.1073/pnas.1431057100
7. Bainbridge DR, Ellis SA, Sargent IL. HLA-G suppresses proliferation of CD4(+) T-lymphocytes. J Reprod Immunol 2000; 48:17-26; PMID: 10996380; http://dx.doi.org/10.1016/S0165-0378 (00)00070-X
8. Contini P, Ghio M, Poggi A, Filaci G, Indiveri F, Ferrone S, Puppo F. Soluble HLA-A,-B,-C and-G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation. Eur J Immunol 2003; 33:125-34; PMID:12594841; http://dx.doi.org/10.1002/immu.200390015
9. Riteau B, Menier C, Khalil-Daher I, Sedlik C, Dausset J, Rouas-Freiss N, Carosella ED. HLA-G inhibits the allogeneic proliferative response. J Reprod Immunol 1999; 43:203-11; PMID:10479056; http://dx.doi.org/ 10.1016/S0165-0378(99)00034-0
10. Rouas-Freiss N, Moreau P, LeMaoult J, Carosella ED. The dual role of HLA-G in cancer. J Immunol Res 2014; 2014:359748; PMID:24800261; http://dx.doi. org/10.1155/2014/359748
11. Moreau P, Mouillot G, Rousseau P, Marcou C, Dausset J, Carosella ED. HLA-G gene repression is reversed by demethylation. Proc Natl Acad Sci USA 2003; 100:1191-6; PMID:12552087; http://dx.doi.org/ 10.1073/pnas.0337539100
12. Castelli EC, Mendes-Junior CT, Deghaide NH, de Albuquerque RS, Muniz YC, Simoes RT, Carosella ED, Moreau P, Donadi EA. The genetic structure of 3' untranslated region of the HLA-G gene: polymorphisms and haplotypes. Genes Immun 2010; 11:134-41; PMID:19798077; http://dx.doi.org/10.1038/ gene.2009.74
13. Castelli EC, Moreau P, Oyae Chiromatzo A, Mendes-Junior CT, Veiga-Castelli LC, Yaghi L, Giuliatti S, Carosella ED, Donadi EA. In silico analysis of micro-RNAS targeting the HLA-G 3' untranslated region alleles and haplotypes. Hum Immunol 2009; 70:1020-5; PMID:19664672; http://dx.doi.org/10.1016/j. humimm.2009.07.028
14. Manaster I, Goldman-Wohl D, Greenfield C, Nachmani D, Tsukerman P, Hamani Y, Yagel S, Mandelboim O. MiRNA-mediated control of HLA-G expression and function. PLoS One 2012; 7:e33395; PMID:22438923; http://dx.doi.org/10.1371/journal. pone.0033395
15. Bukur J, Rebmann V, Grosse-Wilde H, Luboldt H, Ruebben H, Drexler I, Sutter G, Huber C, Seliger B. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63:4107-11; PMID:12874014
16. Nuckel H, Rebmann V, Durig J, Duhrsen U, Grosse-Wilde H. HLA-G expression is associated with an unfavorable outcome and immunodeficiency in chronic lymphocytic leukemia. Blood 2005; 105:1694-8; PMID:15466928; http://dx.doi.org/10.1182/blood-2004-08-3335
17. Sayed D, Badr G, Maximous D, Mikhail NN, Abu-Tarboush F, Alhazza IM. HLA-G and its relation to proliferation index in detection and monitoring breast cancer patients. Tissue Antigens 2010; 75:40-7; PMID:20196818; http://dx.doi.org/10.1111/j.1399-0039.2009.01393.x
18. Singer G, Rebmann V, Chen YC, Liu HT, Ali SZ, Reinsberg J, McMaster MT, Pfeiffer K, Chan DW, Wardelmann E et al. HLA-G is a potential tumor marker in malignant ascites. Clin Cancer Res 2003; 9:4460-4; PMID:14555519
19. Amiot L, Ferrone S, Grosse-Wilde H, Seliger B. Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? Cell Mol Life Sci 2011; 68:417-31; PMID:21063893; http://dx.doi.org/10.1007/ s00018-010-0583-4
20. Veit TD, Chies JA. Tolerance versus immune response-microRNAs as important elements in the regulation of the HLA-G gene expression. Transpl Immunol 2009; 20:229-31; PMID:19038339; http://dx.doi.org/ 10.1016/j.trim.2008.11.001
21. Wang X, Li B, Wang J, Lei J, Liu C, Ma Y, Zhao H. Evidence that miR-133a causes recurrent spontaneous abortion by reducing HLA-G expression. Reprod Biomed Online 2012; 25:415-24; PMID:22877943; http://dx.doi.org/10.1016/j.rbmo. 2012.06.022
22. Kawakami K, Enokida H, Chiyomaru T, Tatarano S, Yoshino H, Kagara I, Gotanda T, Tachiwada T, Nishiyama K, Nohata N et al. The functional significance of miR-1 and miR-133a in renal cell carcinoma. Eur J Cancer 2012; 48:827-36; PMID:21745735; http://dx. doi.org/10.1016/j.ejca.2011.06.030
23. Kinoshita T, Nohata N, Fuse M, Hanazawa T, Kikkawa N, Fujimura L, Watanabe-Takano H, Yamada Y, Yoshino H, Enokida H et al. Tumor suppressive microRNA-133a regulates novel targets: moesin contributes to cancer cell proliferation and invasion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 2012; 418:378-83; PMID:22266319; http://dx.doi.org/10.1016/j.bbrc. 2012.01.030
24. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer 2012; 106:405-13; PMID:22068816; http:// dx.doi.org/10.1038/bjc.2011.462
25. Moriya Y, Nohata N, Kinoshita T, Mutallip M, Okamoto T, Yoshida S, Suzuki M, Yoshino I, Seki N. Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. J Hum Genet 2012; 57:38-45; PMID:22089643; http:// dx.doi.org/10.1038/jhg.2011.126
26. Song YX, Yue ZY, Wang ZN, Xu YY, Luo Y, Xu HM, Zhang X, Jiang L, Xing CZ, Zhang Y. MicroRNA-148b is frequently down-regulated in gastric cancer and acts as a tumor suppressor by inhibiting cell proliferation. Mol Cancer 2011; 10:1; PMID:21205300; http://dx.doi.org/10.1186/1476-4598-10-1
27. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, Inazawa J. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 2011; 71:6450-62; PMID:21868754; http://dx.doi. org/10.1158/0008-5472.CAN-11-0364
28. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y et al. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014; 33:378-86; PMID:23318422; http://dx. doi.org/10.1038/onc.2012.575
29. Zhou X, Zhao F, Wang ZN, Song YX, Chang H, Chiang Y, Xu HM. Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation. Oncol Rep 2012; 27:447-54; PMID:21971665; http://dx.doi.org/10.3892/or.2011.1482
30. Zhou Y, Wu D, Tao J, Qu P, Zhou Z, Hou J. Micro-RNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol 2013; 47:423-32; PMID:23206218; http://dx.doi.org/10.3109/00365599.2012.748821
31. Zhu C, Li J, Ding Q, Cheng G, Zhou H, Tao L, Cai H, Li P, Cao Q, Ju X et al. miR-152 controls migration and invasive potential by targeting TGFalpha in prostate cancer cell lines. Prostate 2013; 73:1082-9; PMID:23460133; http://dx.doi. org/10.1002/pros.22656
32. Consiglio CR, Veit TD, Monticielo OA, Mucenic T, Xavier RM, Brenol JC, Chies JA. Association of the HLA-G gene C3142C>G polymorphism with systemic lupus erythematosus. Tissue Antigens 2011; 77:540-5; PMID:21395561; http://dx.doi.org/ 10.1111/j.1399-0039.2011.01635.x
33. Tan Z, Randall G, Fan J, Camoretti-Mercado B, Brockman-Schneider R, Pan L, Solway J, Gern JE, Lemanske RF, Nicolae D et al. Allele-specific targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet 2007; 81:829-34; PMID:17847008; http://dx.doi.org/10.1086/521200
34. Braun J, Misiak D, Busch B, Krohn K, Huttelmaier S. Rapid identification of regulatory microRNAs by miTRAP (miRNA trapping by RNA in vitro affinity purification). Nucleic Acids Res 2014; 42(8): e66; PMID:24510096; http://dx.doi.org/10.1093/ nar/gku127
35. Bukur J, Seliger B. The role of HLA-G for protection of human renal cell-carcinoma cells from immunemediated lysis: implications for immunotherapies. Semin Cancer Biol 2003 (b); 13:353-9; PMID:14708715; http://dx.doi.org/10.1016/S1044-579X(03)00026-9
36. Zhu XM, Han T, Wang XH, Li YH, Yang HG, Luo YN, Yin GW, Yao YQ. Overexpression of miR-152 leads to reduced expression of human leukocyte antigen-G and increased natural killer cell mediated cytolysis in JEG-3 cells. Am J Obstet Gynecol 2010; 202:592 e1-7; PMID:20430358; http://dx.doi.org/10.1016/j. ajog.2010.03.002
37. Gonen-Gross T, Achdout H, Arnon TI, Gazit R, Stern N, Horejsi V, Goldman-Wohl D, Yagel S, Mandelboim O. The CD85J/leukocyte inhibitory receptor-1 distinguishes between conformed and β2-microglobulin-free HLA-G molecules. J Immunol 2005; 175:4866-74; PMID:16210588; http://dx.doi.org/ 10.4049/jimmunol.175.8.4866
38. Howangyin KY, Loustau M, Wu J, Alegre E, Daouya M, Caumartin J, Sousa S, Horuzsko A, Carosella ED, Lemaoult J. Multimeric structures of HLA-G isoforms function through differential binding to LILRB receptors. Cell Mol Life Sci 2012; PMID:22802125; http:// dx.doi.org/10.1007/s00018-012-1069-3.
39. Havens MA, Reich AA, Duelli DM, Hastings ML. Biogenesis of mammalian microRNAs by a non-canonical processing pathway. Nucleic Acids Res 2012; 40:4626-40; PMID:22270084; http://dx.doi.org/10.1093/nar/ gks026
40. Jiao J, Herl LD, Farese RV, Gao FB. MicroRNA-29b regulates the expression level of human progranulin, a secreted glycoprotein implicated in frontotemporal dementia. PLoS One 2010; 5:e10551; PMID:20479936; http://dx.doi.org/10.1371/journal. pone.0010551
41. Tuncel T, Karagoz B, Haholu A, Ozgun A, Emirzeoglu L, Bilgi O, Kandemir EG. Immunoregulatory Function of HLA-G in Gastric Cancer. Asian Pac J Cancer Prev 2013; 14:7681-4; PMID:24460353; http://dx.doi.org/ 10.7314/APJCP.2013.14.12.7681
42. Girgis AH, Iakovlev VV, Beheshti B, Bayani J, Squire JA, Bui A, Mankaruos M, Youssef Y, Khalil B, Khella H et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 2012; 72:5273-84; PMID:22926558; http://dx.doi.org/10.1158/0008-5472.CAN-12-0656
43. Kuroda N, Tamura M, Shiotsu T, Nakamura S, Taguchi T, Tominaga A, Hes O, Michal M, Kawada C, Shuin T et al. Chromosomal abnormalities of clear cell renal cell carcinoma: frequent gain of chromosome 7. Pathol Int 2010; 60:9-13; PMID:20055946; http://dx. doi.org/10.1111/j.1440-1827.2009.02467.x
44. Reid-Nicholson MD, Motiwala N, Drury SC, Peiper SC, Terris MK, Waller JL, Ramalingam P. Chromosomal abnormalities in renal cell carcinoma variants detected by Urovysion fluorescence in situ hybridization on paraffin-embedded tissue. Ann Diagn Pathol 2011; 15:37-45; PMID:21238914; http://dx.doi.org/ 10.1016/j.anndiagpath.2010.07.011
45. Long XR, He Y, Huang C, Li J. MicroRNA-148a is silenced by hypermethylation and interacts with DNA methyltransferase 1 in hepatocellular carcinogenesis. Int J Oncol 2014; 44:1915-22; PMID:24714841; http://dx.doi.org/10.3892/ijo.2014.2373
46. Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y, Qi YT, Xu Q, Li W, Lu B et al. A regulatory circuit of miR-148a/152 and DNMT1 in modulating cell transformation and tumor angiogenesis through IGF-IR and IRS1. J Mol Cell Biol 2013; 5:3-13; PMID:22935141; http://dx. doi.org/10.1093/jmcb/mjs049
47. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR et al. Real-time quantification of micro-RNAs by stem-loop RT-PCR. Nucleic Acids Res 2005; 33:e179; PMID:16314309; http://dx.doi.org/10.1093/ nar/gni178
48. Varkonyi-Gasic E, Wu R, Wood M, Walton EF, Hellens RP. Protocol: a highly sensitive RT-PCR method for detection and quantification of microRNAs. Plant Methods 2007; 3:12; PMID:17931426; http://dx.doi. org/10.1186/1746-4811-3-12
49. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP. Tissue microarrays for highthroughput molecular profiling of tumor specimens. Nat Med 1998; 4:844-7; PMID:9662379; http://dx. doi.org/10.1038/nm0798-844
50. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. IARC Press 2004
51. Bukur J, Herrmann F, Handke D, Recktenwald C, Seliger B. Identification of E2F1 as an important transcription factor for the regulation of tapasin expression. J Biol Chem 2010; 285:30419-26; PMID:20663889; http://dx.doi.org/10.1074/jbc.M109.094284
52. Real LM, Cabrera T, Collado A, Jimenez P, Garcia A, Ruiz-Cabello F, Garrido F. Expression of HLA G in human tumors is not a frequent event. Int J Cancer 1999; 81:512-8; PMID:10225437; http://dx.doi.org/ 10.1002/(SICI)1097-0215(19990517)81:4%3c512:: AID-IJC2%3e3.0.CO;2-O
53. Hirata H, Matsuyama H, Matsumoto H, Korenaga Y, Ohmi C, Sakano S, Yoshihiro S, Naito K. Deletion mapping of 18q in conventional renal cell carcinoma. Cancer Genet Cytogenet 2005; 163:101-105; PMID:16337851; http://dx.doi.org/10.1016/j. cancergencyto.2005.03.010
54. Jasinski-Bergner S, Mandelboim O, Seliger B. The role of microRNAs in the control of innate immune response in cancer. J Natl Cancer Inst 2014; 106(10); PMID:25217579; http://dx.doi.org/10.1093/jnci/ dju257
55. Jasinski-Bergner S, Stehle F, Gonschorek E, Kalich J, Schulz K, Huettelmaier S, Braun J, Seliger B. Identification of 14-3-3beta Gene as a Novel miR-152 Target Using a Proteome-based Approach. J Biol Chem 2014; 289:31121-35; PMID:25228695; http://dx.doi.org/ 10.1074/jbc.M114.556290
56. Jiang F, Richter J, Schraml P, Bubendorf L, Gasser T, Sauter G, Mihatsch MJ, Moch H. Chromosomal imbalances in papillary renal cell carcinoma: genetic differences between histological subtypes. Am J Pathol 1998; 153:1467-3; PMID:9811338; http://dx.doi.org/ 10.1016/S0002-9440(10)65734-3
57. Nohata N, Hanazawa T, Kikkawa N, Sakurai D, Sasaki K, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nakagawa M et al. Identification of novel molecular targets regulated by tumor suppressive miR-1/miR-133a in maxillary sinus squamous cell carcinoma. N Int J Oncol 2011;39:1099-107; PMID:21701775; http:// dx.doi.org/10.3892/ijo.2011.1096.
58. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Kawahara K, Nishiyama K, Seki N, Nakagawa M. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol 2013; 31:115-23; PMID:21396852; http://dx. doi.org/10.1016/j.urolonc.2010.09.017